Introduction to Testing for Antibiotic Resistance

August 19, 2020

Robert H. Christenson, PhD, describes the threat of AMR and the role of relevant diagnostics in clinical settings.

Robert H. Christenson, PhD, Professor of Pathology and Professor of Medical and Research Technology, describes the burden of AMR and the role of diagnostics in slowing it.

Related coverage:

Bringing 2 to 4 Antibiotics for AMR to Market by 2030 | John Parkinson |

JUL 10, 2020

Over 20 biopharmaceutical companies have joined together to launch an initiative to develop 2-4 antibiotics in 10 years for antimicrobial resistance (AMR).

To aid with the research and development, the companies announced the launch of the AMR Action Fund, and that they raised nearly $1 billion thus far.

The AMR Action Fund, an initiative of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), an international body representing the R&D pharmaceutical industry, was announced at simultaneous virtual launch events in Berlin and Washington, DC on Thursday with a third event in Tokyo scheduled for today.

The AMR Action Fund expects to invest its current funding as well as future support from partners to address the funding gap for the financing of antibiotic development.

“With the AMR Action Fund, the pharmaceutical industry is investing nearly $1 billion to sustain an antibiotic pipeline that is on the verge of collapse, a potentially devastating situation that could affect millions of people around the world,” Chairman and CEO of Eli Lilly and Company and President of IFPMA David Ricks said.

Read the full story.